Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical has announced a 2025 H Shareholders class meeting to discuss and potentially approve resolutions for granting the board a general mandate to repurchase H Shares and A Shares. This move aims to preserve company value and protect shareholder interests, reflecting a strategic effort to strengthen its market position and enhance shareholder value.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development, manufacture, and sale of pharmaceutical products, medical devices, and healthcare services, with a market presence in China and internationally.
Average Trading Volume: 5,143,571
Technical Sentiment Signal: Sell
Current Market Cap: HK$62.5B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.